Dr. Durden is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3855 Health Sciences Dr
La Jolla, CA 92093Phone+1 858-822-7580Fax+1 858-822-0022- Is this information wrong?
Summary
- Dr. Donald Durden is a pediatric hematologist/oncologist in La Jolla, CA and is affiliated with Rady Children's Hospital - San Diego. He received his medical degree from University of Miami Miller School of Medicine and has been in practice 32 years. He specializes in cancer genetics/cancer risk assessment and solid tumor/neuro-oncology experimental therapeutics and is experienced in asparaginase, pathologic neovascularization, phosphatidylinositol 3-kinases, phosphorylation, and signal transducing adaptor proteins. He is a physician scientist with over 25 years of continuous NIH RO1 grant funding involved heavily into in silico drug discovery and development around novel molecular targets which include kinase, immuno-oncologic and epigenetic targets from target discovery efforts ongoing in his laboratory over the past 20 years.
Education & Training
- University of WashingtonFellowship, Pediatric Hematology/Oncology, 1988 - 1993
- University of WashingtonResidency, Pediatrics, 1987 - 1988
- Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 1985 - 1987
- University of Miami Leonard M. Miller School of MedicineClass of 1985
- University of Miami School of MedicinePhD, 1979 - 1983
- University of South FloridaB.S., Microbiology and Zoology, 1971 - 1977
Certifications & Licensure
- GA State Medical License Current
- NE State Medical License 2018 - 2022
- CA State Medical License 2010 - 2019
- American Board of Pediatrics Pediatric Hematology-Oncology
- Pediatric Hematology-OncologyPediatric Hematology-Oncology
Awards, Honors, & Recognition
- Editorial Board Molecular Cancer Research AACR, 2009
- TME NIH Study Section NIH, 2002-2007
- Cancer Working Group USWNR, 2012
- Join now to see all
Clinical Trials
- A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors Start of enrollment: 2007 Apr 01
- A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas Start of enrollment: 2010 Aug 01
Publications & Presentations
PubMed
- 16 citationsBinding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection.Kendra R Vann, Arpan Acharya, Suk Min Jang, Catherine Lachance, Mohamad Zandian, Tina A Holt, Audrey L Smith, Kabita Pandey, Donald L Durden, Dalia El-Gamal, Jacques C...> ;Structure. 2022 Sep 1
- 12 citationsPI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron.Arpan Acharya, Anup S Pathania, Kabita Pandey, Michellie Thurman, Kendra R Vann, Tatiana G Kutateladze, Kishore B Challagundala, Donald L Durden, Siddappa N Byrareddy> ;Clinical and Translational Medicine. 2022 Apr 1
- 1 citationsPreclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic LeukemiaYongsheng Ruan, Hye Na Kim, Heather Ogana, Zesheng Wan, Samantha Hurwitz, Cydney Nichols, Nour Abdel-Azim, Ariana Coba, Seyoung Seo, Yong-Hwee Eddie Loh, Eun Ji Gang, ...> ;Frontiers in Oncology. 2021 Dec 1
- Join now to see all
Press Mentions
- Potential New Anti-Cancer Drug Class Inhibits Multiple Molecular TargetsFebruary 2nd, 2017
- Potential New Drug Class Hits Multiple Cancer Cell Targets, Boosting Efficacy and SafetyFebruary 1st, 2017
Grant Support
- Development of dual inhibitor of PI3K/BRD4 for cancer therapeuticsNIH NCI2017–2022
- Role of PTEN and PI-3 kinase in medulloblastomagenesisNIH NCI2017–2022
- Overcoming BTK inhibitor resistance in B-cell malignanciesNIH NCI2019–2020
- Maximum MYC control using dual PI-3K/BRD4 inhibitorsNIH NCI2018–2020
- Phase I trial of dual PI-3K/BRD4 inhibitor SF1126 in hepatocellular carcinomaFDA2016–2020
- Vascular Targeted PAN PI-3 Kinase Inhibitor Prodrug, SF1126 For Glioma TherapyNational Cancer Institute2010–2012
- Role Of SYK And RAC2 In Regulation Of Hif1alpha And Neovascularization.National Heart, Lung, And Blood Institute2009–2010
- Role Of SYK And RAC2 In Regulation Of Hif1alpha And Neovascularization.National Heart, Lung, And Blood Institute2009
- Vascular Targeted PAN PI-3 Kinase Inhibitor Prodrug, SF1126 For Glioma TherapyNational Cancer Institute2009
- Vascular Targeted PAN Pi-3kinase Inhibitor Prodrug, SF1126 For Glioma Therapy.National Cancer Institute2008
- Pten/Aktp53 Signaling Axis In Tumor Induced AngiogenesisNational Cancer Institute2004–2006
- Pten/Aktp53 Signaling Axis In Tumor Induced AngiogenesisNational Cancer Institute2002–2003
- RAC2 In Integrin Macrophage FunctionNational Heart, Lung, And Blood Institute2002
- Vascular Endothelial Cell Integrins In AngiogenesisNational Cancer Institute2000–2002
- Phase II Study For Treatment Of Pediatric Brain TumorsNational Cancer Institute1999
- Phase II Study For Treatment Of Pediatric Brain TumorsNational Cancer Institute1997–1998
Hospital Affiliations
- Rady Children's Hospital - San DiegoSan Diego, California
Industry Relationships
- Founder, SignalRx Pharmaceuticals Inc.Founder drug discovery group combinatorial in silico drug discovery multiple targets kinase, epigenetic and immuno-oncologic in natureDisclosure: Shareholder in this private company2012 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: